Central venous catheters (CVCs) are essential in pediatric oncology but are associated with a considerable risk of complications, particularly in immunocompromised patients. Evidence from low- and middle-income settings remains limited. This prospective observational study was conducted from 2020 to 2023 at a tertiary pediatric oncology center. A total of 141 patients (younger than 18 y), including 382 CVCs, were followed for 5869 catheter-days. Clinical, laboratory, and catheter-related data were collected. Complication rates were expressed per 1000 catheter-days, and risk factors were analyzed using univariate and multivariate models. CVC-related complications occurred in 97/382 devices (25.4%), and mortality was 0.3%. Infectious complications were most frequent (53.1%), followed by vascular (32.8%) and mechanical events (14.1%). Gram-positive organisms predominated in peripheral cultures (26.5%), while Gram-negative pathogens were more common in central cultures (22.4%). Patients with complications had significantly lower leukocyte counts ( P =0.001), neutrophils ( P <0.001), lymphocytes ( P =0.006), and platelets ( P =0.002), with higher D-dimer levels ( P <0.001). Hematological malignancy independently increased complication risk ( P =0.002), while alcohol disinfection of catheter hubs was protective ( P =0.007). Thrombosis represented 85.7% of vascular events and was managed conservatively in most cases. CVC-related complications remain common in pediatric oncology and are influenced by disease-related and modifiable factors. Strengthening infection control practices may significantly reduce complications.
No takes yet. Share an insight, caveat, or question.
Elhabashy et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: